{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T08:46:10Z","timestamp":1772268370765,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bprch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.beha.2014.07.005","type":"journal-article","created":{"date-parts":[[2014,7,18]],"date-time":"2014-07-18T13:46:02Z","timestamp":1405691162000},"page":"121-127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["It is time to change thrombosis risk assessment for PV and ET?"],"prefix":"10.1016","volume":"27","author":[{"given":"Francesco","family":"Passamonti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenica","family":"Caramazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Mora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosario","family":"Casalone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margherita","family":"Maffioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.beha.2014.07.005_bib1","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","article-title":"Proposals and rationale for revision of the world health organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel","volume":"110","author":"Tefferi","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2014.07.005_bib2","doi-asserted-by":"crossref","first-page":"485","DOI":"10.18632\/oncotarget.281","article-title":"Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies","volume":"2","author":"Passamonti","year":"2011","journal-title":"Oncotarget"},{"issue":"25","key":"10.1016\/j.beha.2014.07.005_bib3","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2014.07.005_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.beha.2014.07.005_bib5","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1056\/NEJMc1400499","article-title":"JAK inhibitor in CALR-mutant myelofibrosis","volume":"370","author":"Passamonti","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.beha.2014.07.005_bib6","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/leu.2014.33","article-title":"Looking for CALR mutations in familial myeloproliferative neoplasms","volume":"28","author":"Maffioli","year":"2014","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.beha.2014.07.005_bib7","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","article-title":"Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia","volume":"117","author":"Passamonti","year":"2004","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.beha.2014.07.005_bib8","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.beha.2014.07.005_bib9","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2008.72","article-title":"Life expectancy and prognostic factors in the classic BCR\/ABL-negative myeloproliferative disorders","volume":"22","author":"Cervantes","year":"2008","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.beha.2014.07.005_bib10","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European leukemianet","volume":"29","author":"Barbui","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2014.07.005_bib11","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2012-02-366054","article-title":"How I treat polycythemia vera","volume":"120","author":"Passamonti","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2014.07.005_bib12","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/leu.2011.334","article-title":"How to manage polycythemia vera","volume":"26","author":"Passamonti","year":"2012","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.beha.2014.07.005_bib13","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.beha.2014.07.005_bib14","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1200\/JCO.2007.15.3569","article-title":"Leukocytosis and risk stratification assessment in essential thrombocythemia","volume":"26","author":"Carobbio","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.beha.2014.07.005_bib15","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","article-title":"Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera","volume":"109","author":"Landolfi","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2014.07.005_bib16","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood-2007-07-102665","article-title":"Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey","volume":"111","author":"Ruggeri","year":"2008","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2014.07.005_bib17","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/ajh.21508","article-title":"Essential thrombocythemia and pregnancy: observations from recent studies and management recommendations","volume":"84","author":"Tefferi","year":"2009","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.beha.2014.07.005_bib18","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1182\/blood-2007-01-071068","article-title":"Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation","volume":"110","author":"Passamonti","year":"2007","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.beha.2014.07.005_bib19","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.clml.2011.01.002","article-title":"Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis","volume":"11","author":"Passamonti","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1016\/j.beha.2014.07.005_bib20","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1111\/j.1538-7836.2009.03531.x","article-title":"Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia","volume":"7","author":"Passamonti","year":"2009","journal-title":"J\u00a0Thromb Haemost"},{"issue":"7","key":"10.1016\/j.beha.2014.07.005_bib21","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2012-04-424911","article-title":"Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort","volume":"120","author":"Campbell","year":"2012","journal-title":"Blood"},{"issue":"9501","key":"10.1016\/j.beha.2014.07.005_bib22","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.beha.2014.07.005_bib23","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2005.05858.x","article-title":"The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia","volume":"132","author":"Cheung","year":"2006","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.beha.2014.07.005_bib24","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1600-0609.2006.00688.x","article-title":"JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status","volume":"77","author":"Heller","year":"2006","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.beha.2014.07.005_bib25","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.10634","article-title":"Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status","volume":"92","author":"Finazzi","year":"2007","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.beha.2014.07.005_bib26","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.exphem.2007.08.011","article-title":"The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia","volume":"35","author":"Hsiao","year":"2007","journal-title":"Exp Hematol"},{"issue":"7","key":"10.1016\/j.beha.2014.07.005_bib27","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/sj.leu.2404666","article-title":"Thrombosis can occur at any phase of essential thrombocythemia with JAK2(V617F) mutation: a single institutional study in Japan","volume":"21","author":"Ohyashiki","year":"2007","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.beha.2014.07.005_bib28","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1365-2141.2007.06755.x","article-title":"JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets","volume":"139","author":"Toyama","year":"2007","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.beha.2014.07.005_bib29","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2014.07.005_bib30","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/sj.leu.2404693","article-title":"Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients","volume":"21","author":"Alvarez-Larran","year":"2007","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.beha.2014.07.005_bib31","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1002\/cncr.22663","article-title":"Clinical correlates of JAK2V617F allele burden in essential thrombocythemia","volume":"109","author":"Kittur","year":"2007","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.beha.2014.07.005_bib32","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/sj.leu.2404755","article-title":"The quantitative JAK2 V617F neutrophil allele burden does not correlate with thrombotic risk in essential thrombocytosis","volume":"21","author":"Pemmaraju","year":"2007","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.beha.2014.07.005_bib33","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.leukres.2006.09.005","article-title":"Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders","volume":"31","author":"Speletas","year":"2007","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.beha.2014.07.005_bib34","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3324\/haematol.11653","article-title":"Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia","volume":"93","author":"Antonioli","year":"2008","journal-title":"Haematologica"},{"issue":"9464","key":"10.1016\/j.beha.2014.07.005_bib35","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.beha.2014.07.005_bib36","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2141.2005.05764.x","article-title":"JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance","volume":"131","author":"Wolanskyj","year":"2005","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.beha.2014.07.005_bib37","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3324\/haematol.12970","article-title":"Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain","volume":"93","author":"Ziakas","year":"2008","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.beha.2014.07.005_bib38","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1182\/blood-2011-08-371328","article-title":"Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome","volume":"119","author":"Giona","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2014.07.005_bib39","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1182\/blood-2010-11-316810","article-title":"Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations","volume":"117","author":"Passamonti","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2014.07.005_bib40","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A\u00a0prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.beha.2014.07.005_bib41","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1182\/blood-2013-02-486050","article-title":"Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms","volume":"121","author":"Rumi","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2014.07.005_bib42","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2009.47","article-title":"TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.beha.2014.07.005_bib43","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.beha.2014.07.005_bib44","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2014.07.005_bib45","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","article-title":"A\u00a0prognostic model to predict survival in 867 world health organization-defined essential thrombocythemia at diagnosis: a study by the international working group on myelofibrosis research and treatment","volume":"120","author":"Passamonti","year":"2012","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.beha.2014.07.005_bib46","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an international prognostic score of thrombosis in world health organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.beha.2014.07.005_bib47","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2014.07.005_bib48","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.leu.2404473","article-title":"A\u00a0unified definition of clinical resistance\/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group","volume":"21","author":"Barosi","year":"2007","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.beha.2014.07.005_bib49","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.beha.2014.07.005_bib50","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","article-title":"Assessment and prognostic value of the European leukemianet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera","volume":"119","author":"Alvarez-Larran","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2014.07.005_bib51","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s00277-013-1683-7","article-title":"Clinical evaluation of the European leukemianet response criteria in patients with essential thrombocythemia treated with anagrelide","volume":"92","author":"Hernandez-Boluda","year":"2013","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.beha.2014.07.005_bib52","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"issue":"26","key":"10.1016\/j.beha.2014.07.005_bib53","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an international prognostic score of thrombosis in who-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2014.07.005_bib54","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/cncr.28441","article-title":"A\u00a0phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea","volume":"120","author":"Verstovsek","year":"2014","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.beha.2014.07.005_bib55","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2006-03-009860","article-title":"High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a","volume":"108","author":"Kiladjian","year":"2006","journal-title":"Blood"},{"issue":"32","key":"10.1016\/j.beha.2014.07.005_bib56","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera","volume":"27","author":"Quintas-Cardama","year":"2009","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692614000462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692614000462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T20:34:55Z","timestamp":1565642095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692614000462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S1521692614000462"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2014.07.005","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"It is time to change thrombosis risk assessment for PV and ET?","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2014.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}